You are here

A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients

Last updated on December 17, 2017

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Little Rock, Arkansas, 72205 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Epilepsy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-60 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- A diagnosis and history of epilepsy for which they are on 0-2 concurrent antiepileptic
drugs.

- On a stable dose of their current AED(s) for 4 weeks prior to the Screening Visit.

- Must be in good health (with the exception of epilepsy), as determined by the Primary
Investigator via the medical history, a physical examination, and screening laboratory
investigations.

- A body mass index (BMI) between 18 and 35.

- Able and willing to give written informed consent prior to participation in the study.

- A reproducible IPS-induced photo-paroxysmal EEG response (PPR) of at least 3 points on
a frequency assessment scale in at least one eye condition and no change of more than
3 frequencies in 2 repeated measurements recorded at the Screening Visit.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of non-epileptic seizures (metabolic, structural, or pseudoseizures).

- History of status epilepticus while on any antiepileptic medication.

- The etiology of the seizures is due to any of the following; progressive degenerative
disease, metabolic illness, active infection, demyelination, drugs, alcohol.

- The subject has used benzodiazepines (oral, intra-muscular, or suppository) as escape
medication within the past 6 months.

- The subject has taken an investigational medication within 30 days prior to the Day 1.

- Women who are pregnant or lactating.

- An active Central Nervous System (CNS) infection, demyelinating disease, degenerative
neurological disease or any CNS disease deemed to be progressive during the course of
the study that may confound the interpretation of the study results.

- The subject has a clinically significant (e.g., cancerous, unstable, progressive,
functionally disabling, or infectious) medical condition that would interfere with the
ability to complete the study or that might interfere with the absorption,
distribution, metabolism, and/or excretion of drugs.

- Subjects with impaired hepatic function [ALT (Alanine aminotransferase), AST
(Aspartate aminotransferase) =3 times the upper limit of normal] or any clinically
significant laboratory abnormality that, in the opinion of the investigator, would
increase the risk of participation or interfere with the interpretatio of the study
results.

- History of alcoholism, drug abuse, or drug addiction within the last 12 months.

- Clinically significant psychiatric illness, psychological or behavioral problem which,
in the opinion of the investigator would interfere with the subject's ability to
participate in the study OR the subject is receiving therapy with neuroleptic drugs.

- Subject experiences a clinical seizure during any IPS procedure performed during the
screening period.

NCT00979004
Pfizer
Terminated
A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients
A Phase 2, Multi-Center, Single-Blind, Placebo-Controlled Pharmacodynamic Evaluation of ICA-105665 in Epilepsy Patients With a Photo-Induced Paroxysmal EEG Response
Subjects with epilepsy with a documented photoparoxysmal response to intermittent photic stimulation (IPS) will participate. Four subjects will be enrolled at each dose level and will receive a single dose of placebo and a single dose of ICA-105665 during the study, each followed by intermittent photic stimulation. The effects of ICA-105665 on the photoparoxysmal electroencephalography (EEG) response of each group will be reviewed before the dose is selected for each subsequent group of subjects.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Epilepsy
Drug: ICA-105665
Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
Experimental: ICA-105665
Intervention: Drug: ICA-105665
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
13
September 2010
September 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • A diagnosis and history of epilepsy for which they are on 0-2 concurrent antiepileptic drugs.
  • On a stable dose of their current AED(s) for 4 weeks prior to the Screening Visit.
  • Must be in good health (with the exception of epilepsy), as determined by the Primary Investigator via the medical history, a physical examination, and screening laboratory investigations.
  • A body mass index (BMI) between 18 and 35.
  • Able and willing to give written informed consent prior to participation in the study.
  • A reproducible IPS-induced photo-paroxysmal EEG response (PPR) of at least 3 points on a frequency assessment scale in at least one eye condition and no change of more than 3 frequencies in 2 repeated measurements recorded at the Screening Visit.

Exclusion Criteria:

  • History of non-epileptic seizures (metabolic, structural, or pseudoseizures).
  • History of status epilepticus while on any antiepileptic medication.
  • The etiology of the seizures is due to any of the following; progressive degenerative disease, metabolic illness, active infection, demyelination, drugs, alcohol.
  • The subject has used benzodiazepines (oral, intra-muscular, or suppository) as escape medication within the past 6 months.
  • The subject has taken an investigational medication within 30 days prior to the Day 1.
  • Women who are pregnant or lactating.
  • An active Central Nervous System (CNS) infection, demyelinating disease, degenerative neurological disease or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results.
  • The subject has a clinically significant (e.g., cancerous, unstable, progressive, functionally disabling, or infectious) medical condition that would interfere with the ability to complete the study or that might interfere with the absorption, distribution, metabolism, and/or excretion of drugs.
  • Subjects with impaired hepatic function [ALT (Alanine aminotransferase), AST (Aspartate aminotransferase) =3 times the upper limit of normal] or any clinically significant laboratory abnormality that, in the opinion of the investigator, would increase the risk of participation or interfere with the interpretatio of the study results.
  • History of alcoholism, drug abuse, or drug addiction within the last 12 months.
  • Clinically significant psychiatric illness, psychological or behavioral problem which, in the opinion of the investigator would interfere with the subject's ability to participate in the study OR the subject is receiving therapy with neuroleptic drugs.
  • Subject experiences a clinical seizure during any IPS procedure performed during the screening period.
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00979004
ICA-105665-04
B5311005
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now